title: Neostigmine-induced hyperglycemia is mediated by central muscarinic receptor in fed rats.
abstract: We previously reported that neostigmine injected into the third cerebral ventricle stimulated adrenal secretion of epinephrine, secretion of glucagon from the pancreas, and direct neural innervation of the liver, resulting in hepatic venous plasma hyperglycemia in anesthetized fed rats. However, receptor type of these 3 mechanisms is not known. Therefore, we examined the effects of intraventricularly injected cholinergic or adrenergic antagonists on neostigmine-induced catecholamines in intact rats, glucagon secretion which is mediated by direct neural innervation of pancreas in bilateral adrenalectomized (ADX) rats, and hepatic venous hyperglycemia which is mediated by direct neural innervation of liver in ADX rats receiving constant infusion of somatostatin from femoral vein. Atropine injected into the third cerebral ventricle suppressed epinephrine secretion and dose-dependently inhibited hepatic venous hyperglycemia induced by neostigmine in intact rats. The neostigmine-induced glucagon secretion which occurs in ADX rats was suppressed by atropine. Atropine also prevented the neostigmine-induced hyperglycemia in ADX rats receiving constant somatostatin infusion through femoral vein (ADX-Somato rats). On the other hand, phentolamine, propranolol and hexamethonium showed no significant inhibitory effect on neostigmine-induced hyperglycemia, epinephrine and glucagon secretion in intact rats, glucagon secretion in ADX rats, or hyperglycemia in ADX-Somato rats. These results suggest that neostigmine-induced epinephrine and glucagon secretion and increased hepatic glucose output stimulated by direct neural innervation to liver is mediated by central muscarinic receptor in fed rats.
authors.affiliation: Third Department of Internal Medicine, Nagoya University School of Medicine, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Iguchi
authors.forename: A
authors.initials: A
authors.lastname: Yatomi
authors.forename: M
authors.initials: M
authors.lastname: Gotoh
authors.forename: H
authors.initials: H
authors.lastname: Matsunaga
authors.forename: K
authors.initials: K
authors.lastname: Uemura
authors.forename: H
authors.initials: H
authors.lastname: Miura
authors.forename: T
authors.initials: T
authors.lastname: Satake
authors.forename: T
authors.initials: T
authors.lastname: Tamagawa
authors.forename: N
authors.initials: N
authors.lastname: Sakamoto
mesh_terms: D000320:Adrenergic Fibers / Q000187:drug effects / Q000502:physiology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D006943:Hyperglycemia / Q000139:chemically induced* / Q000378:metabolism; D007276:Injections, Intraventricular; D008297:Male; D009388:Neostigmine / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology*
chemical_list: D011976:Receptors, Muscarinic; D009388:Neostigmine; D001285:Atropine; D011433:Propranolol